Harbor Capital Advisors Inc. Cuts Holdings in MiMedx Group, Inc $MDXG

Harbor Capital Advisors Inc. trimmed its position in MiMedx Group, Inc (NASDAQ:MDXG) by 71.3% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 335,763 shares of the company’s stock after selling 833,432 shares during the period. Harbor Capital Advisors Inc. owned about 0.23% of MiMedx Group worth $2,344,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the company. CWM LLC grew its holdings in shares of MiMedx Group by 63.8% in the second quarter. CWM LLC now owns 4,857 shares of the company’s stock valued at $30,000 after acquiring an additional 1,892 shares in the last quarter. Rhumbline Advisers boosted its position in MiMedx Group by 1.4% in the first quarter. Rhumbline Advisers now owns 177,156 shares of the company’s stock worth $1,346,000 after purchasing an additional 2,436 shares during the last quarter. SkyView Investment Advisors LLC grew its stake in MiMedx Group by 3.6% in the 2nd quarter. SkyView Investment Advisors LLC now owns 87,734 shares of the company’s stock valued at $523,000 after purchasing an additional 3,032 shares during the period. Police & Firemen s Retirement System of New Jersey grew its stake in MiMedx Group by 14.9% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 28,135 shares of the company’s stock valued at $172,000 after purchasing an additional 3,642 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of MiMedx Group by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company’s stock valued at $559,000 after purchasing an additional 4,049 shares during the last quarter. Institutional investors own 79.15% of the company’s stock.

Insider Activity at MiMedx Group

In related news, insider Kimberly Maersk-Moller sold 58,300 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $7.42, for a total transaction of $432,586.00. Following the sale, the insider directly owned 236,982 shares in the company, valued at approximately $1,758,406.44. This represents a 19.74% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 1.70% of the company’s stock.

MiMedx Group Trading Up 1.1%

Shares of MDXG opened at $7.08 on Friday. The business has a 50-day moving average of $7.05 and a 200 day moving average of $6.88. MiMedx Group, Inc has a fifty-two week low of $5.79 and a fifty-two week high of $9.71. The firm has a market cap of $1.05 billion, a P/E ratio of 26.20 and a beta of 1.64. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.95 and a current ratio of 4.41.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings data on Monday, November 13th. The company reported ($0.03) EPS for the quarter. The business had revenue of $67.69 million for the quarter. MiMedx Group had a net margin of 10.38% and a return on equity of 27.19%. As a group, research analysts forecast that MiMedx Group, Inc will post 0.3 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Wall Street Zen raised shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a report on Sunday, November 2nd. Mizuho lowered their price objective on shares of MiMedx Group from $12.00 to $10.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 17th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of MiMedx Group in a research report on Monday. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.00.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.